British journal of cancer · 2026
Clinical significance of circulating macrophage markers across different stages of prostate cancer: highlighting soluble CD163.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hansen Emma B, Antonsen Kristian W, Jochumsen Mads R, Salachan Paul V, Bouchelouche Kirsten, Hansen Torben F, Osther Palle J S, Zedan Ahmed H, Borre Michael, Møller Holger J, Sørensen Karina D
Аннотация
BACKGROUND: The clinical significance of circulating macrophage markers in prostate cancer (PC) is largely unexplored. Here, we hypothesised that serum levels of the macrophage markers CD163 and SIRPα might be associated with disease aggressiveness and hold prognostic potential in PC, where novel prognostic biomarkers are needed.
METHODS: Soluble CD163 (sCD163) and SIRPα (sSIRPα) were measured in serum by enzyme-linked immunosorbent assays in three PC cohorts representing different disease stages (N = 646 patients in total). Prognostic results in metastatic castration-resistant PC (mCRPC) were validated in an independent cohort (N = 161).
RESULTS: Serum levels of sCD163 and sSIRPα were significantly higher in patients with metastatic vs localised PC (p < 0.05). In general, serum sCD163 and sSIRPα levels were not associated with clinical parameters of disease aggressiveness in patients with hormone-sensitive PC (p > 0.05). In mCRPC, high serum sCD163 levels predicted shorter progression-free survival (PFS) on first-line treatment independent of standard clinical parameters in both the training and validation cohort (training: HR: 1.77 (1.12-2.78), p = 0.014; validation: HR: 1.85 (1.15-2.97), p = 0.011).
CONCLUSIONS: Circulating levels of sCD163 and sSIRPα were increased in patients with metastatic compared to localised PC. Further, higher sCD163 levels predicted worse PFS in mCRPC, suggesting potential as a future minimally-invasive biomarker to aid mCRPC prognostication.
METHODS: Soluble CD163 (sCD163) and SIRPα (sSIRPα) were measured in serum by enzyme-linked immunosorbent assays in three PC cohorts representing different disease stages (N = 646 patients in total). Prognostic results in metastatic castration-resistant PC (mCRPC) were validated in an independent cohort (N = 161).
RESULTS: Serum levels of sCD163 and sSIRPα were significantly higher in patients with metastatic vs localised PC (p < 0.05). In general, serum sCD163 and sSIRPα levels were not associated with clinical parameters of disease aggressiveness in patients with hormone-sensitive PC (p > 0.05). In mCRPC, high serum sCD163 levels predicted shorter progression-free survival (PFS) on first-line treatment independent of standard clinical parameters in both the training and validation cohort (training: HR: 1.77 (1.12-2.78), p = 0.014; validation: HR: 1.85 (1.15-2.97), p = 0.011).
CONCLUSIONS: Circulating levels of sCD163 and sSIRPα were increased in patients with metastatic compared to localised PC. Further, higher sCD163 levels predicted worse PFS in mCRPC, suggesting potential as a future minimally-invasive biomarker to aid mCRPC prognostication.